EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Upfront Autologous Stem Cell Transplantation in First Complete Remission for Advanced‐Stage Extra‐Nodal NK /T‐Cell Lymphoma: A Multicenter Retrospective Study

Shaoxuan Hu, Weiping Liu, Linjun Zhao, Wenrong Huang, Zhenyang Gu, Huiqiang Huang, Liping Su, Hui Zhou, Haisheng Liu, Tao Wu, Liling Zhang, Xia He und 7 weitere

American Journal of Hematology · 2026

DOI: 10.1002/ajh.70415 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Shaoxuan Hu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Inst…. Hauptthemen laut MEDLINE: Lymphoma, Extranodal NK-T-Cell, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Capital's Funds for Health Improvement and Research, Beijing Municipal Administration of Hospitals Incubating Program, Science Foundation of Peking University Cancer Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study was to evaluate the effect of upfront autologous stem cell transplantation (ASCT) on the prognosis in patients with advanced‐stage extra‐nodal NK/T‐cell lymphoma (NKTCL) achieving first complete remission (CR1) after frontline therapy. To this end, we retrospectively reviewed data from patients diagnosed with stage III or IV NKTCL who achieved CR1 after frontline treatment between 2006 and 2023 at 14 medical centers in China. A total of 107 patients were included in this study. The majority of patients (87%) received non‐anthracycline‐based first‐line chemotherapy, and 38 (36%) received upfront ASCT consolidation at the time of CR1. With a median follow‐up time of 39.8 months, progression‐free survival (PFS) and overall survival (OS) rates were significantly better in the ASCT group than in the non‐ASCT group (3‐year PFS: 78.2% vs. 54.6%, p = 0.005; 3‐year OS: 86.0% vs. 68.9%, p = 0.04). However, in the subgroup of patients receiving non‐anthracycline‐based chemotherapy ( N = 93), ASCT was significantly associated with better PFS (3‐year PFS: 77.6% vs. 59.3%, p = 0.025) but not with OS (3‐year OS: 85.6% vs. 74.8%, p = 0.164). In multivariate analyzes, upfront ASCT was an independent predictor of better PFS (hazard ratio [HR] = 0.37, 95% confidence interval [CI]: 0.15–0.88, p = 0.025) but not OS after adjusting for baseline prognostic index of NK‐cell lymphoma (PINK), types of first‐line chemotherapy, and local radiotherapy. After propensity score matched analyzes, upfront ASCT remained significantly associated with better PFS but not with OS. These real‐world data suggest upfront ASCT prolongs PFS in patients with advanced‐stage NKTCL in CR1, yet its impact on OS remains unclear.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Extranodal NK-T-CellHematopoietic Stem Cell TransplantationHumansRetrospective StudiesFemaleMaleTransplantation, AutologousRemission InductionMiddle AgedAdultNeoplasm StagingAntineoplastic Combined Chemotherapy ProtocolsPrognosisYoung Adult

Stichwörter der Autor:innen

ASCTNK/T‐cell lymphomaNKCTLsurvival

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
  • Department of Lymphoma, Peking University International Hospital, Beijing, China.
  • Department of Hematology, the Fifth Medical Center of PLA General Hospital, Beijing, China.
  • Department of Hematology, the First Medical Center of PLA General Hospital, Beijing, China.
  • Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Department of Hematology, Shanxi Medical University Affiliated Cancer Hospital/Shanxi Provincial Cancer Hospital/Chinese Academy of Medical Sciences Cancer Hospital Shanxi Hospital, Taiyuan, Shanxi, China.

ORCID-Profile: Jun Zhu

Förderung

  • Capital's Funds for Health Improvement and Research
  • Beijing Municipal Administration of Hospitals Incubating Program
  • Science Foundation of Peking University Cancer Hospital
  • Wu Jieping Medical Foundation

Zitieren

APA

Hu, S., Liu, W., Zhao, L., Huang, W., Gu, Z., Huang, H., Su, L., Zhou, H., Liu, H., Wu, T., Zhang, L., He, X., Shi, M., Wang, H., Wang, X., Zhu, J., Li, Y., Qi, S., & Song, Y. (2026). Upfront Autologous Stem Cell Transplantation in First Complete Remission for Advanced‐Stage Extra‐Nodal NK /T‐Cell Lymphoma: A Multicenter Retrospective Study. American Journal of Hematology. https://doi.org/10.1002/ajh.70415

Vancouver

Hu S, Liu W, Zhao L, Huang W, Gu Z, Huang H, et al. Upfront Autologous Stem Cell Transplantation in First Complete Remission for Advanced‐Stage Extra‐Nodal NK /T‐Cell Lymphoma: A Multicenter Retrospective Study. American Journal of Hematology. 2026. doi:10.1002/ajh.70415

BibTeX
@article{Hu2026,
  author = {Hu, Shaoxuan and Liu, Weiping and Zhao, Linjun and Huang, Wenrong and Gu, Zhenyang and Huang, Huiqiang and Su, Liping and Zhou, Hui and Liu, Haisheng and Wu, Tao and Zhang, Liling and He, Xia and Shi, Mei and Wang, Hua and Wang, Xiaopei and Zhu, Jun and Li, Yexiong and Qi, Shunan and Song, Yuqin},
  title = {Upfront Autologous Stem Cell Transplantation in First Complete Remission for Advanced‐Stage Extra‐Nodal NK /T‐Cell Lymphoma: A Multicenter Retrospective Study},
  journal = {American Journal of Hematology},
  year = {2026},
  doi = {10.1002/ajh.70415}
}
Kostenlos starten →